1. Home
  2. Disease & Disorders
  3. New York, NY
  4. Cure Cdkl5 Epilepsy Foundation

Cure Cdkl5 Epilepsy Foundation

  • New York, NY
  • Tax-exempt since 2024
  • EIN: 99-1303165
cure5.foundation ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate

Organization summary

Cure Cdkl5 Epilepsy Foundation is a 501(c)(3) organization, classified under Disease & Disorders (NTEE G54). Contributions are tax-deductible.

241 Central Park W Apt 8D, New York, NY 10024-4545

In fiscal year 2024 it reported $192,305 in revenue and $14,000 in expenses, with contributions making up 100.0% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2024 Form 990

Line 13 includes $14,000 paid to Unravel Biosciences for scientific services to generate datasets to support drug repurposing and potentially development. This represents the first payment, the second of which will be due in 2025.

Main program · fiscal year 2024

  • In 2024, CURE5 raised $192k to advance research and therapeutic development for CDKL5 Deficiency Disorder. The Foundation paid $14k to Unravel Biosciences which provided specialized scientific services supporting preclinical research. Specifically, Unravel Biosciences leveraged its AI-driven RNA analysis for a rapid drug repurposing screen. The data collected will be used in partnership with other… Read more

    In 2024, CURE5 raised $192k to advance research and therapeutic development for CDKL5 Deficiency Disorder. The Foundation paid $14k to Unravel Biosciences which provided specialized scientific services supporting preclinical research. Specifically, Unravel Biosciences leveraged its AI-driven RNA analysis for a rapid drug repurposing screen. The data collected will be used in partnership with other CURE5 grantees. In addition, the Foundation designed and launched its grantmaking framework, identified research collaborators, and initiated planning for larger research grants to be awarded in 2025. These activities represent the Foundation's first year of programmatic operations in pursuit of its exempt purpose of supporting scientific discovery and treatments for CDKL5 Deficiency Disorder. The principal project funded in 2025 will be an iPSC portfolio with Boston Children's and building on our repurposing work with several other partners.

    $14,000 spent

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$192,305Fiscal year 20242023: $020232024: $192,3052024
Expenses$14,000Fiscal year 20242023: $020232024: $14,0002024
Total assets—Fiscal year 2024
Total liabilities—Fiscal year 2024
Fiscal year ending December 2024
Revenue$192,305
Expenses$14,000
Net income$178,305
Net assets$178,305

Notable sources of revenue

Percent of total revenue
Contributions$192,305
Program services$0
Investment income$0
Other (net)$0

Assets / debt

Total assets—
Total liabilities—
Net assets$178,305

Compensation

Not in our extract for this year.

Fiscal year ending December 2023
Revenue$0
Expenses$0
Net income$0
Net assets$0

Notable sources of revenue

Percent of total revenue
Contributions$0
Program services$0
Investment income$0
Other (net)$0

Assets / debt

Total assets—
Total liabilities—
Net assets$0

Compensation

Not in our extract for this year.

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?